Table TDI-11. Characteristics of new clients treated for drug problems: demographics and main drug at treatment in 2002 or most recent year available. Part (ii) Main drug (percentage) and of those the percent injecting it (italics)
Country |
|
Opiates |
% inj |
Cocaine |
% inj |
Amphet amines |
% inj |
Ecstasy |
Hallucin ogens |
% inj |
Cannabis |
Others |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Belgium |
(1) |
21 |
7 |
5 |
5 |
14 |
3 |
3 |
1 |
0 |
44 |
12 |
|
Czech Republic |
(2) |
16.7 |
81.6 |
0.1 |
na |
50.6 |
81.6 |
4.1 |
0.4 |
5 |
22.7 |
5.4 |
|
Denmark |
(3) |
35 |
28 |
4 |
7 |
8 |
5 |
2 |
0 |
0 |
33.6 |
9 |
|
Germany |
(4) |
30 |
na |
7 |
na |
10 |
na |
na |
1 |
na |
48 |
4 |
|
Greece |
|
84.3 |
56.3 |
1.5 |
11.5 |
0.1 |
0 |
0.6 |
0.1 |
0 |
11 |
2.4 |
|
Spain |
|
28 |
20 |
42 |
6 |
1 |
6 |
2 |
0.1 |
9 |
23 |
3.9 |
|
France |
(5) |
63.4 |
20.6 |
5.2 |
10.4 |
0.3 |
8.3 |
1.3 |
0.4 |
0 |
25.6 |
3.8 |
|
Ireland |
(6) |
47.4 |
99.6 |
1.7 |
0 |
1 |
0.4 |
10.6 |
0.4 |
0 |
35.4 |
3.5 |
|
Italy |
(7) |
na |
na |
na |
na |
na |
na |
na |
na |
na |
na |
na |
|
Latvia |
(8) |
69.6 |
93.7 |
0.9 |
0 |
10 |
na |
0 |
0.5 |
0 |
6.4 |
12.6 |
|
Lithuania |
(9) |
83.9 |
na |
0.2 |
na |
3 |
na |
na |
0.2 |
na |
0.2 |
12.5 |
|
Luxembourg |
|
na |
na |
na |
na |
na |
na |
na |
na |
na |
na |
na |
|
Hungary |
(11) |
na |
na |
na |
na |
na |
na |
na |
na |
na |
na |
na |
|
Netherlands |
(12) |
22 |
18 |
41 |
1 |
4 |
4 |
2 |
0 |
0 |
28 |
3 |
|
Austria |
(13) |
100 |
100 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
Portugal |
(14) |
na |
na |
na |
na |
na |
na |
na |
na |
na |
na |
na |
|
Slovenia |
|
73.9 |
99.6 |
0.8 |
0 |
0.2 |
0 |
0.8 |
0 |
0 |
22.7 |
1.6 |
|
Slovakia |
|
51.6 |
78.6 |
0.6 |
0 |
14.5 |
43.4 |
0.5 |
0.8 |
0 |
17.9 |
14.1 |
|
Finland |
|
21 |
82.8 |
0.3 |
82.1 |
31.7 |
65.8 |
1.4 |
0 |
0 |
39.6 |
6 |
|
Sweden |
(15) |
22 |
9 |
3 |
0 |
19 |
18 |
3 |
0 |
0 |
35 |
18 |
|
United Kingdom |
(16) |
na |
na |
na |
na |
na |
na |
na |
na |
na |
na |
na |
|
|
|
|
|
Notes: |
|
|
|
|
|
Data were not available for: Estonia, Cyprus, Malta, Poland and Norway. |
|
|
Injecting as a route of administration is not reported for cannabis. |
Belgium |
(1) |
Data refer only to outpatient treatment centres. Last data available refer to 1999. |
|
Czech Republic |
(2) |
Data refer to all treatment centres. |
|
Denmark |
(3) |
Injecting use for opiates refers only to heroin, and cocaine only to cocaine CIH. For distribution by main drug only clients attending outpatient centres. |
|
Germany |
(4) |
Data only refer to outpatient treatment centres; information about injecting use is not available. Amphetamines also include ecstasy. |
|
France |
(5) |
The last available data on treatment demand are reported, referring to the annual census on clients in treatment carried out in November 1999. |
|
Ireland |
(6) |
Last data available refer to 2000. |
|
Italy |
(7) |
Data only refer to outpatient treatment centres; information about injecting opiate use refers only to heroin, for cocaine only to cocaine CIH. |
|
Latvia |
(8) |
Data refer only to outpatient treatment centres. |
|
Lithuania |
(9) |
Amphetamines include all stimulants. |
|
Luxembourg |
(10) |
Data on first treatment only partially available. |
|
Hungary |
(11) |
39% of clients are reported to use hypnotics/sedatives, 18% other substances. |
|
Netherlands |
(12) |
Data refer only to outpatient treatment centres. |
|
Austria |
(13) |
Data refer to clients in substitution treatment only; figures for opiates as main drug and injecting use are consequently 100%. |
|
Sweden |
(15) |
Data refer only to outpatient treatment centres. |
|
United Kingdom |
(16) |
Data relate to the period from 1 April 2001 to 31 March 2002 for Scotland and Northern Ireland; for England and Wales six months data ending 30 September 2000 plus six months data ending 31 March 2001. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sources: 2003 Reitox national reports, Standard table 3, see [Table TDI-10 Part (iii)] for details on sources. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|